Interface Labs is a technology company.
Interface Labs has raised $230K across 1 funding round.
Interface Labs has raised $230K in total across 1 funding round.
Interface Labs has raised $230K in total across 1 funding round.
Interface Labs's investors include Antler.
Interface Laboratories is a biotechnology startup founded in 2021, specializing in infectious disease management through innovative diagnostics, targeted therapeutics, and computational tools.[1] It serves clinicians, researchers, healthcare systems, and patients by solving gaps in diagnostics and treatment, such as rapid pathogen detection and antimicrobial optimization, with products like *C. difficile* assays, novel antifungals, and the BioGPU platform for metagenomic analysis.[1] The company demonstrates growth through preclinical developments, beta launches, active clinical services, and partnerships with healthcare institutions.[1]
Interface Laboratories was founded in 2021 by a pediatric infectious disease specialist with expertise in microbiome research and bioinformatics.[1] The idea emerged from bridging clinical practice with technology to address unmet needs in infectious disease treatment, evolving from the founder's hands-on experience in pediatrics and research into a full-spectrum biotech venture spanning diagnostics, drug discovery, and computational biology.[1] Early traction includes promising data from *C. difficile* diagnostics and the beta launch of the BioGPU platform, alongside therapeutic monitoring services in clinical settings.[1]
Interface Laboratories rides the wave of precision medicine and computational biology in biotech, where rising antimicrobial resistance and post-pandemic diagnostics needs amplify demand for rapid, targeted tools.[1] Timing aligns with advances in machine learning for microbiome analysis and metagenomics, enabling faster pathogen profiling amid global infectious disease threats.[1] Market forces like healthcare partnerships and regulatory pushes for innovative diagnostics favor its bench-to-bedside model, positioning it to influence ecosystem-wide improvements in patient outcomes and research efficiency.[1]
Interface Laboratories is poised to scale its BioGPU platform and preclinical compounds into commercial diagnostics and therapeutics, potentially expanding partnerships amid growing biotech investment in infectious diseases.[1] Trends like AI-driven drug discovery and personalized monitoring will shape its path, evolving its influence from niche innovator to key player in global health tech. This builds on its founding mission, turning clinical gaps into scalable impact.
Interface Labs has raised $230K across 1 funding round. Most recently, it raised $230K Seed in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $230K Seed | Antler |